LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Peptides like retatrutide and similar weight loss compounds sometimes come in larger vials
Not approved by the FDA, EMA, or any regulatory authority for therapeutic use.
Lu SC: Regulation of hepatic glutathione synthesis: current concepts and controversies
Drip menu items span Myers cocktail, immune support, glutathione, energy boost, athletic drip, anti-aging drip, and Cinderella drip